Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-04-03
2007-04-03
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S265100, C424S268100, C424S272100, C424S193100, C424S194100, C514S002600, C514S008100, C514S012200, C530S300000, C530S324000, C530S332000
Reexamination Certificate
active
10379417
ABSTRACT:
The invention presents vaccine formulations comprising highly antigenic epitopes identified within the semi-conserved loop-I of domain III that are capable of eliciting parasite growth inhibitory antibodies. The cyclized or linear peptides can be applied by known adjuvants or be encapsulated by or attached onto the surface of liposomes or virosomes (IRIVs) which serve as human compatible antigen delivery systems. Both cyclized and linear versions of the peptide antigens are surprisingly effective in eliciting immune responses that are cross-reactive with parasite-expressed AMA-1.
REFERENCES:
patent: 7029685 (2006-04-01), Lanar et al.
patent: 7060276 (2006-06-01), Lanar et al.
patent: 7101556 (2006-09-01), Pan
patent: 2003/0032787 (2003-02-01), Lanar et al.
patent: 2004/0019971 (2004-02-01), Rhodes
patent: 2004/0063190 (2004-04-01), Pan
patent: 2004/0175392 (2004-09-01), Pluschke et al.
patent: PCT/AU89/00056 (1989-08-01), None
patent: WO 89/07645 (1989-08-01), None
patent: PCT/US92/02207 (1992-10-01), None
patent: WO 92/16616 (1992-10-01), None
patent: WO 2002/16439 (2002-02-01), None
patent: WO 2002/77195 (2002-03-01), None
patent: WO 2002/52014 (2002-07-01), None
patent: WO 2002/72625 (2002-09-01), None
patent: PCT/EP2004/002126 (2004-09-01), None
Mueller et al, Infection and Immunity, Aug. 2003, 71/8:4749-4758.
Silvie et al, JBC, Mar. 5, 2004, 279/10:9490-9496.
Pye et al, Infection and Immunity, Jul. 1991, 59/7:2403-2411.
Crewther et al, Infection and Immunity, Aug. 1996, 64/8:3310-3317.
Lal et al, Infection and Immuity, Mar. 1996, 64/3:1054-1059.
Fu et al, HBC, Oct. 10, 1997, 272/41:25678-25684.
Amante et al, J. Immunology, 1997, 159:5535-5544.
Cubillos et al, Biochimie, 2003, 84:1181-1188.
Mitchell et al, Infection and Immunity, Jan. 2004, 72/1:154-158.
Anders et al, Parasitology Today, 2000, 16/10:444-447.
Urquiza et al, Vaccine, 2001, 19:508-513.
Arevalo-Herrera et al, Molecular Immunology, 2001, 38:443-455.
Salvatore et al, Vaccine, 2002, 20:3477-3484.
Polley et al, Vaccine, 2004, 23:718-728.
Shi et al, Vaccine, 2000, 18:2902-2914.
Kocken et al, Molecular and Biochemical Parasitology, 2000, 109:147-156.
Donahue et al, Molecular and Biochemical Parasitology, 2000, 111:15-30.
Figtree et al, Molecular and Biochemical Parasitology, 2000, 108:53-66.
Feng et al, J. Mol. Biol., 2005, 350:641-656.
Bruns et al, Vaccine, 2003, 21:1843-1852.
Salazar et al, FEBS Letters, 2002, 527:95-100.
Fraser et al, Molecular and Biochemical Parasitology, 2001, 117:49-59.
Heppner et al, Vaccine, 2005, 23:2243-2250.
Amit, A. G. et al., “Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution,”Science233:747-753 (1986).
Anders, R. F. et al., “Immunisation with recombinant AMA-1 protects mice against infection withPlasmodium chabaudi,” Vaccine16:240-247 (1998).
Beeli, Reto et al., “A Tricyclic Template Derived from (2S,4R)-4-Hydroxyproline for the Synthesis of Protein Loop Mimetics,”Helvetica Chimica Acta79:2235-2248.
Bisang, Christian et al., “Protein-Loop Mimetics: A Diketopiperazine-Based Template to Stabilize Loop Conformation in Cyclic Peptides Containing the NPNA and RGD Motifs,”Helvetica Chimica Acta79:1825-1842 (1996).
Cheng, Qin et al., “Sequence Analysis of the Apical Membrane Antigen I (AMA-1) ofPlasmodium vivax”, Mol. Biochem. Parasitol.65:183-187 (1994).
Christodoulides, Myron et al., “Immunization with Recombinant Class 1 Outer-Membrane Protein fromNeisseria Meningitidus: Influence of Liposomes and Adjuvants on Antibody Avidity, Recognition of Native Protein and the Induction of a Bactericidal Immune Response Against Meningococci,”Microbiology,144:3027-3037 (1998).
Cohen, S. et al., “Gamma globulin and acquired immunity to human malaria,”Nature192:733-737 (1961).
Coley, Andrew M. et al., “Rapid and precise epitope mapping of monoclonal antibodies againstPlasmodium falciparumAMA1 by combined phage display of fragments and random peptides,”Protein Eng14:691-698 (2001).
Collins, W. E. et al., “Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 ofPlasmodium fragile,” Am. J. Trop. Med. Hyg.51:711-719 (1994).
Crewther, P. E. et al., “Plasmodium falciparum: two antigens of similar size are located in different compartments of the rhoptry,”Exp. Parasitol.70:193-206 (1990).
Crewther, P. E. et al., “Protective immune responses to apical membrane antigen 1 ofPlasmodium chabaudiinvolve recognition of strain-specific epitopes,”Infect. Immun.64:3310-3317 (1996).
Deans, J. A. et al., “Vaccination trials in rhesus monkeys with a minor, invariant,Plasmodium knowlesi66kD merozoite antigen,”Parasite Immunol.10:535-552 (1988).
Deans, Judith A. et al., “Rat monoclonal antibodies which inhibit the in vitro multiplication ofPlasmodium knowlesi,” Clin. Exp. Immunol.49:297-309 (1982).
Dorn, Arnulf et al., “Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein,”Nature374:269-271 (1995).
Escalante, Ananias A. et al., Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) ofPlasmodium falciparum. X. Asembo Bay Cohort Project. Mol. Biochem. Parasitol. 113:279-287 (2001).
Favre, Michel et al., “Structural Mimicry of Canonical Conformations in Antibody Hypervariable Loops Using Cyclic Peptides Containing a Heterochiral Diproline Template,”J. Am. Chem. Soc.121:2679-2685 (1999).
Fries, Louis F. et al., “Liposomal Malaria Vaccine in Humans: A Safe and Potent Adjuvant Strategy,”Proc. Natl. Acad. Sci. USA,89:358-362 (Jan. 1992).
Gluck, Reinhard, “Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs),”Vaccine17:1782-1787 (1999).
Gomme, Peter. T. et al., “Evaluation of a pepscan approach to identify epitopes recognised by anti-hTSH monoclonal antibodies,”J. Biochem. Biophys. Methods38:53-70 (1999).
Hodder, Anthony N. et al., “Specificity of the protective antibody response to apical membrane antigen 1,”Infect. Immun.69:3286-3294 (May 2001).
Hodder, Anthony N. et al., “The disulfide bond structure of Plasmodium apical membrane antigen-1,”J. Biol. Chem.271:29446-29452 (1996).
Howell, Steven A. et al., “Proteolytic processing and primary structure ofPlasmodium falciparumapical membrane antigen-1,”J. Biol. Chem.276:31311-31320 (2001).
Kocken, Clemens H.M. et al., “Precise timing of expression of aPlasmodium falciparum-derived transgene inPlasmodium bergheiis a critical determinant of subsequent subcellular localization,”J. Biol. Chem.273:15119-15124 (1998).
Kocken, Clemens H.M. et al., “High-level expression of the malaria blood-stage vaccine candidatePlasmodium falciparumapical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion,”Infect. Immun.70:4471-4476 (2002).
Kocken, Clemens, H.M. et al., “Molecular characterisation ofPlasmodium reichenowiapical membrane antigen-1 (AMA-1), comparison withP. falciparumAMA-1, and antibody-mediated inhibition of red cell invasion,”Mol. Biochem. Parasitol.109:147-156 (2000).
Kumar, Sanjai et al., “Vaccines against asexual stage malaria parasites,”Chem. Immunol.80:262-286 (2002).
Lambros, Chris and Vanderberg, J. P., “Synchronization ofPlasmodium falciparumerythrocytic stages in culture,”J. Parasitol.65:418-420 (1979).
Marshall, Vikki M. et al., “Diversity of the vaccine candidate AMA-1 ofPlasmodium falciparum,” Mol. Biochem. Parasitol.77:109-113 (1996).
Marshall, Vikki M. et al., “Structure of the apical membrane antigen I (AMA-1) ofPlasmodium chabaudi,” Mol. Biochem. Parasitol.37:281-283 (1989).
Miller, Louis H. and Hoffman, Stephen L., “Research toward vaccines against malaria,”Nat. Med. Vaccine Supp.4:520-524 (May 1998).
Moreno, Rafael et al., “Exploiting conformationally constrained peptidomimetics and an effici
Freund-Renard Annabelle
Markus Mueller
Pluschke Gerd
Robinson John
Zurbriggen Rinaldo
Minnifield Nita
Pluschke, Gerd et al.
Proskauer Rose LLP
LandOfFree
Compositions and methods for the generation of protective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the generation of protective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the generation of protective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3762080